|
1
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009.PubMed/NCBI View
Article : Google Scholar
|
|
2
|
Otto T and Sicinski P: Cell cycle proteins
as promising targets in cancer therapy. Nat Rev Cancer. 17:93–115.
2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Dominguez-Brauer C, Thu KL, Mason JM,
Blaser H, Bray MR and Mak TW: Targeting mitosis in cancer: Emerging
strategies. Mol Cell. 60:524–536. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Dong X, Fu J, Yin X, Cao S, Li X, Lin L,
Huyiligeqi and Ni J: Emodin: A review of its pharmacology,
toxicity and pharmacokinetics. Phytother Res. 30:1207–1218.
2016.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
Merino JJ, Durán AG, Chinchilla N and
Macías FA: Biological activities of hydroxyanthracene derivatives
(HADs) from Aloe species and their potential uses. Phytochem Rev.
24:2387–2415. 2025.
|
|
6
|
Sharifi-Rad J, Herrera-Bravo J, Kamiloglu
S, Petroni K, Mishra AP, Monserrat-Mesquida M, Sureda A, Martorell
M, Aidarbekovna DS, Yessimsiitova Z, et al: Recent advances in the
therapeutic potential of emodin for human health. Biomed
Pharmacother. 154(113555)2022.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Li Y, Li K, Zhao Y, Li Y, Li D, Shen L,
Wang Q, Yang HS and Sun Z: Emodin-8-O-β-D-glucopyranoside, a
natural hydroxyanthraquinone glycoside from plant, suppresses
cancer cell proliferation via p21-CDKs-Rb axis. Toxicol Appl
Pharmacol. 438(115909)2022.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Liu W, Qaed E, Zhu Y, Tian W, Wang Y, Kang
L, Ma X and Tang Z: Research progress and new perspectives of
anticancer effects of emodin. Am J Chin Med. 51:1751–1793.
2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Gabrielli B, Brooks K and Pavey S:
Defective cell cycle checkpoints as targets for anti-cancer
therapies. Front Pharmacol. 3(9)2012.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Sherr CJ and McCormick F: The RB and p53
pathways in cancer. Cancer Cell. 2:103–112. 2002.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Kastan MB and Bartek J: Cell-cycle
checkpoints and cancer. Nature. 432:316–323. 2004.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Negrini S, Gorgoulis VG and Halazonetis
TD: Genomic instability-an evolving hallmark of cancer. Nat Rev Mol
Cell Biol. 11:220–228. 2010.PubMed/NCBI View
Article : Google Scholar
|
|
13
|
Asghar U, Witkiewicz AK, Turner NC and
Knudsen ES: The history and future of targeting cyclin-dependent
kinases in cancer therapy. Nat Rev Drug Discov. 14:130–146.
2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ding L, Cao J, Lin W, Chen H, Xiong X, Ao
H, Yu M, Lin J and Cui Q: The roles of cyclin-dependent kinases in
cell-cycle progression and therapeutic strategies in human breast
cancer. Int J Mol Sci. 21(1960)2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Pitolli C, Wang Y, Candi E, Shi Y, Melino
G and Amelio I: p53-Mediated tumor suppression: DNA-damage response
and alternative mechanisms. Cancers (Basel).
11(1983)2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Wang Y, Yu H, Zhang J, Ge X, Gao J, Zhang
Y and Lou G: Anti-tumor effect of emodin on gynecological cancer
cells. Cell Oncol (Dordr). 38:353–363. 2015.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Lai JM, Chang JT, Wen CL and Hsu SL:
Emodin induces a reactive oxygen species-dependent and ATM-p53-Bax
mediated cytotoxicity in lung cancer cells. Eur J Pharmacol.
623:1–9. 2009.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Liu R, Liu J, Wang S, Wang Y, Zhang T, Liu
Y, Geng X and Wang F: Combined treatment with emodin and a
telomerase inhibitor induces significant telomere
damage/dysfunction and cell death. Cell Death Dis.
10(527)2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Chen R, Zhang H, Zhao X, Zhu L, Zhang X,
Ma Y and Xia L: Progress on the mechanism of action of emodin
against breast cancer cells. Heliyon. 10(e38628)2024.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Wahi D, Soni D and Grover A: A
double-edged sword: The anti-cancer effects of emodin by inhibiting
the redox-protective protein MTH1 and augmenting ROS in NSCLC. J
Cancer. 12:652–681. 2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Taiyab A, Ashraf A, Sulaimani MN, Rathi A,
Shamsi A and Hassan MI: Role of MTH1 in oxidative stress and
therapeutic targeting of cancer. Redox Biol.
77(103394)2024.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ahmad W, Ansari MA, Alsayari A,
Almaghaslah D, Wahab S, Alomary MN, Jamal QMS, Khan FA, Ali A, Alam
P and Elderdery AY: In vitro, molecular docking and in silico
ADME/Tox studies of emodin and chrysophanol against human
colorectal and cervical carcinoma. Pharmaceuticals (Basel).
15(1348)2022.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Li M, Jin S, Cao Y, Xu J, Zhu S and Li Z:
Emodin regulates cell cycle of non-small lung cancer (NSCLC) cells
through hyaluronan synthase 2 (HA2)-HA-CD44/receptor for hyaluronic
acid-mediated motility (RHAMM) interaction-dependent signaling
pathway. Cancer Cell Int. 21(19)2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Marei HE, Bedair K, Hasan A, Al-Mansoori
L, Gaiba A, Morrione A, Cenciarelli C and Giordano A: Targeting
CDKs in cancer therapy: Advances in PROTACs and molecular glues.
NPJ Precis Oncol. 9(204)2025.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Mihaylova R, Elincheva V, Simeonova R and
Momekov G: Emodin and the anthraquinone scaffold: Therapeutic
promise and strategies to overcome translational barriers.
Molecules. 31(833)2026.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Vermeulen K, Van Bockstaele DR and
Berneman ZN: The cell cycle: A review of regulation, deregulation
and therapeutic targets in cancer. Cell Prolif. 36:131–149.
2003.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wang Y, Zhao M, Li B and Geng X: Advances
in the mechanism of emodin-induced hepatotoxicity. Heliyon.
10(e33631)2024.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Hsu SC and Chung JG: Anticancer potential
of emodin. Biomedicine (Taipei). 2:108–116. 2012.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Fang L, Zhao F, Iwanowycz S, Wang J, Yin
S, Wang Y and Fan D: Anticancer activity of emodin is associated
with downregulation of CD155. Int Immunopharmacol.
75(105763)2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Bertoli C, Skotheim JM and de Bruin RAM:
Control of cell cycle transcription during G1 and S phases. Nat Rev
Mol Cell Biol. 14:518–528. 2013.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Ai Z, Liu B, Chen J, Zeng X, Wang K, Tao
C, Chen J, Yang L, Ding Q and Zhou M: Advances in nano drug
delivery systems for enhanced efficacy of emodin in cancer therapy.
Int J Pharm X. 9(100314)2024.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Topacio BR, Zatulovskiy E, Cristea S, Xie
S, Tambo CS, Rubin SM, Sage J, Kõivomägi M and Skotheim JM: Cyclin
D-Cdk4,6 drives cell-cycle progression via the retinoblastoma
protein's C-terminal helix. Mol Cell. 74:758–770.e4.
2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Sherr CJ and Roberts JM: CDK inhibitors:
Positive and negative regulators of G1-phase progression. Genes
Dev. 13:1501–1512. 1999.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Pellarin I, Dall'Acqua A, Favero A,
Segatto I, Rossi V, Crestan N, Karimbayli J, Belletti B and
Baldassarre G: Cyclin-dependent protein kinases and cell cycle
regulation in biology and disease. Signal Transduct Target Ther.
10(11)2025.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Sui JQ, Xie KP, Zou W and Xie MJ: Emodin
inhibits breast cancer cell proliferation through the
ERα-MAPK/Akt-cyclin D1/Bcl-2 signaling pathway. Asian Pac J Cancer
Prev. 15:6247–6251. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Wei WT, Lin SZ, Liu DL and Wang ZH: The
distinct mechanisms of the antitumor activity of emodin in
different types of cancer (review). Oncol Rep. 30:2555–2562.
2013.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Shieh DE, Chen YY, Yen MH, Chiang LC and
Lin CC: Emodin-induced apoptosis through p53-dependent pathway in
human hepatoma cells. Life Sci. 74:2279–2290. 2004.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Lee CY, Cheng MH, Chen TR, Yang YC, Chung
MI and Chiu HF: Cell cycle regulation of emodin through p53, p21,
and cyclin D pathway in human lung adenocarcinoma A549 cells.
Planta Med. 74(PA124)2008.
|
|
39
|
Abukhdeir AM and Park BH: p21 and p27:
Roles in carcinogenesis and drug resistance. Expert Rev Mol Med.
10(e19)2008.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Huang FJ, Hsuuw YD and Chan WH:
Characterization of apoptosis induced by emodin and related
regulatory mechanisms in human neuroblastoma cells. Int J Mol Sci.
14:20139–20156. 2013.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Shrimali D, Shanmugam MK, Kumar AP, Zhang
J, Tan BKH, Ahn KS and Sethi G: Targeted abrogation of diverse
signal transduction cascades by emodin for the treatment of
inflammatory disorders and cancer. Cancer Lett. 341:139–149.
2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Chihara T, Shimpo K, Beppu H, Yamamoto N,
Kaneko T, Wakamatsu K and Sonoda S: Effects of aloe-emodin and
emodin on proliferation of the MKN45 human gastric cancer cell
line. Asian Pac J Cancer Prev. 16:3887–3891. 2015.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Ullah Z, de Renty C and DePamphilis ML:
Checkpoint kinase 1 prevents cell cycle exit linked to terminal
cell differentiation. Mol Cell Biol. 31:4129–4143. 2011.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Gupta A, Dagar G, Chauhan R, Sadida HQ,
Almarzooqi SK, Hashem S, Uddin S, Macha MA, Akil ASAS, Pandita TK,
et al: Cyclin-dependent kinases in cancer: Role, regulation, and
therapeutic targeting. Adv Protein Chem Struct Biol. 135:21–55.
2023.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Lande PS, Adhao VS, Ambhore JP, Gaikwad
KP, Chandak CS and Joge LP: Anticancer action of naturally
occurring emodin for the controlling of cervical cancer. Explor
Target Antitumor Ther. 4:690–698. 2023.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Su X, Yang W, Yan Z, Hao Z, Jin J, Liu Y,
Wu S and He Y: Targeting tumor metabolism: The dual attack of
emodin on glycolysis and oxidative phosphorylation in esophageal
squamous cell carcinoma. Phytomedicine. 144(156958)2025.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Trybus W, Król T, Trybus E, Stachurska A,
Król G and Kopacz-Bednarska A: Emodin induces death in human
cervical cancer cells through mitotic catastrophe. Anticancer Res.
39:679–686. 2019.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Chen YY, Chiang SY, Lin JG, Yang JS, Ma
YS, Liao CL, Lai TY, Tang NY and Chung JG: Emodin, aloe-emodin and
rhein induced DNA damage and inhibited DNA repair gene expression
in SCC-4 human tongue cancer cells. Anticancer Res. 30:945–951.
2010.PubMed/NCBI
|
|
49
|
Akkol EK, Tatlı II, Karatoprak GŞ, Ağar
OT, Yücel Ç, Sobarzo-Sánchez E and Capasso R: Is emodin with
anticancer effects completely innocent? Two sides of the coin.
Cancers (Basel). 13(2733)2021.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Liu K, Zheng M, Lu R, Du J, Zhao Q, Li Z
and Zhang S: The role of CDC25C in cell cycle regulation and
clinical cancer therapy: A systematic review. Cancer Cell Int.
20(213)2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Tong H, Huang Z, Chen H, Zhou B, Liao Y
and Wang Z: Emodin reverses gemcitabine resistance of pancreatic
cancer cell lines through inhibition of IKKβ/NF-κB signaling
pathway. Onco Targets Ther. 13:9839–9848. 2020.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Kim JY, Jung CW, Lee WS, Jeong HJ, Park
MJ, Jang WI and Kim EH: Emodin coupled with high LET neutron beam-a
novel approach to treat on glioblastoma. J Radiat Res. 63:817–827.
2022.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Sougiannis AT, Kelley B, Velazquez KE,
Enos RT, Bader JE, Chatzistamou I, Pena MM, Nagarkatti M, Carson
sA, Fan D and Murphy EA: Emodin, a natural anthraquinone, may help
protect gastrointestinal health during chemotherapy treatment by
decreasing inflammation of the gastric mucosa and preserving gut
morphology. FASEB J. 33(368.2)2019.
|
|
54
|
Li T, Si W, Zhu J, Yin L and Zhong C:
Emodin reverses 5-Fu resistance in human colorectal cancer via
downregulation of PI3K/Akt signaling pathway. Am J Transl Res.
12:1851–1861. 2020.PubMed/NCBI
|
|
55
|
Chen Y, Liu Y, Gong Z and Huang Z: Emodin
is a novel phosphatidylethanolamine anabolism inhibitor that
reprograms lipid metabolism to overcome 5-fluorouracil resistance
in colorectal cancer. J Pharm Anal. 15(101343)2025.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Cheng K, Zhou J, Zhao Y, Chen Y, Ming L,
Huang D, Yang R, Lin Z and Chen D: pH-responsive and CD44-targeting
polymer micelles based on CD44p-conjugated amphiphilic block
copolymer PEG-b-HES-b-PLA for delivery of emodin to breast cancer
cells. Nanotechnology. 33(275604)2022.PubMed/NCBI View Article : Google Scholar
|
|
57
|
An S, Bing SJ, Cho J, Herath KHINM, Kim A,
Chang HW and Jee Y: Emodin induces apoptosis of concanavalin
A-stimulated murine splenocytes. Food Sci Biotechnol. 25:1693–1700.
2016.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Bhattacharjee M, Upadhyay P, Sarker S,
Basu A, Das S, Ghosh A, Ghosh S and Adhikary A: Combinatorial
therapy of thymoquinone and emodin synergistically enhances
apoptosis, attenuates cell migration and reduces stemness
efficiently in breast cancer. Biochim Biophys Acta Gen Subj.
1864(129695)2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Chen Y, Li J, Hu J, Zheng J, Zheng Z, Liu
T, Lin Z and Lin M: Emodin enhances ATRA-induced differentiation
and induces apoptosis in acute myeloid leukemia cells. Int J Oncol.
45:2076–2084. 2014.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Chen Y, Zheng J, Gan D, Chen Y, Zhang N,
Chen Y, Lin Z, Wang W, Chen H, Lin D and Hu J: E35 ablates acute
leukemia stem and progenitor cells in vitro and in vivo. J Cell
Physiol. 235:8023–8034. 2020.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Chen Y, Gan D, Huang Q, Luo X, Lin D and
Hu J: Emodin and its combination with cytarabine induce apoptosis
in resistant acute myeloid leukemia cells in vitro and in vivo.
Cell Physiol Biochem. 48:2061–2073. 2018.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Thakral F, Prasad B, Sehgal R, Gupta S,
Sharma U, Singh BJ, Sharma B, Tuli HS, Haque S and Ahmad F: Role of
emodin to prevent gastrointestinal cancers: Recent trends and
future prospective. Discov Oncol. 16(468)2025.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Yan YY, Zheng LS, Zhang X, Chen LK, Singh
S, Wang F, Zhang JY, Liang YJ, Dai CL, Gu LQ, et al: Blockade of
Her2/neu binding to Hsp90 by emodin azide methyl anthraquinone
derivative induces proteasomal degradation of Her2/neu. Mol Pharm.
8:1687–1697. 2011.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Lee BH, Huang YY, Duh PD and Wu SC:
Hepatoprotection of emodin and Polygonum multiflorum against
CCl(4)-induced liver injury. Pharm Biol. 50:351–359.
2012.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Zhang Y, Pu W, Bousquenaud M, Cattin S,
Zaric J, Sun L and Rüegg C: Emodin inhibits inflammation,
carcinogenesis, and cancer progression in the AOM/DSS model of
colitis-associated intestinal tumorigenesis. Front Oncol.
10(564674)2021.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Tu Y, Wu Z, Tan B, Yang A and Fang Z:
Emodin: Its role in prostate cancer associated inflammation
(review). Oncol Rep. 42:1259–1271. 2019.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Subramaniam A, Shanmugam MK, Ong TH, Li F,
Perumal E, Chen L, Vali S, Abbasi T, Kapoor S, Ahn KS, et al:
Emodin inhibits growth and induces apoptosis in an orthotopic
hepatocellular carcinoma model by blocking activation of STAT3. Br
J Pharmacol. 170:807–821. 2013.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Pooja T and Karunagaran D: Emodin
suppresses Wnt signaling in human colorectal cancer cells SW480 and
SW620. Eur J Pharmacol. 742:55–64. 2014.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Okon E, Gaweł-Bęben K, Jarzab A, Koch W,
Kukula-Koch W and Wawruszak A: Therapeutic potential of
1,8-dihydroanthraquinone derivatives for breast cancer. Int J Mol
Sci. 24(15789)2023.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Zhang Q, Hao S, Wei G, Liu X and Miao Y:
The p53-mediated cell cycle regulation is a potential mechanism for
emodin-suppressing osteosarcoma cells. Heliyon.
10(e26850)2024.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Ma YS, Weng SW, Lin MW, Lu CC, Chiang JH,
Yang JS, Lai KC, Lin JP, Tang NY, Lin JG and Chung JG: Antitumor
effects of emodin on LS1034 human colon cancer cells in vitro and
in vivo: Roles of apoptotic cell death and LS1034 tumor xenografts
model. Food Chem Toxicol. 50:1271–1278. 2012.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Sun Y, Wang X, Zhou Q, Lu Y, Zhang H, Chen
Q, Zhao M and Su S: Inhibitory effect of emodin on migration,
invasion and metastasis of human breast cancer MDA-MB-231 cells in
vitro and in vivo. Oncol Rep. 33:338–346. 2015.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Zhou L, Hu X, Han C, Niu X, Han L, Yu H,
Pan G and Fu Z: Comprehensive investigation on the metabolism of
emodin both in vivo and in vitro. J Pharm Biomed Anal.
223(115122)2023.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Liu YP, Zhou GH, Song X, Wang YH, Zhang F,
Chen QQ, Cho KW, Jin SN and Wen JF: Emodin protects against
homocysteine-induced cardiac dysfunction by inhibiting oxidative
stress via MAPK and Akt/eNOS/NO signaling pathways. Eur J
Pharmacol. 940(175452)2023.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Peng S, Wang J, Lu C, Xu Z, Chai JJ, Ke Q
and Deng XZ: Emodin enhances cisplatin sensitivity in non-small
cell lung cancer through Pgp downregulation. Oncol Lett.
21(230)2021.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Tang C, Zou Y, Meng H, Xu J, Long F, Chen
X, Xiao Q, Su K, Nan Z, Guo Y and Li C: Synergistic anticancer
effects of carrier-free self-assembled doxorubicin and emodin
nanoparticles in non-small cell lung cancer. Sci Rep.
15(40205)2025.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Dong X, Ni B, Fu J, Yin X, You L, Leng X,
Liang X and Ni J: Emodin induces apoptosis in human hepatocellular
carcinoma HepaRG cells via the mitochondrial caspase-dependent
pathway. Oncol Rep. 40:1985–1993. 2018.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Zhang Q, Chen WW, Sun X, Qian D, Tang DD,
Zhang LL, Li MY, Wang LY, Wu CJ and Peng W: The versatile emodin: A
natural easily acquired anthraquinone possesses promising
anticancer properties against a variety of cancers. Int J Biol Sci.
18:3498–3527. 2022.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Wu CC, Chen MS and Chen JY: The
application of emodin treatment on nasopharyngeal carcinoma
therapy. Biomedicines. 12(486)2024.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Stompor-Gorący M: The health benefits of
emodin, a natural anthraquinone derived from rhubarb-A summary
update. Int J Mol Sci. 22(9522)2021.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Xu C, Luo Y, Ntim M, Quan W, Li Z, Xu Q,
Jiang L, Zhang J, Shang D, Li L, et al: Effect of emodin on long
non-coding RNA-mRNA networks in rats with severe acute
pancreatitis-induced acute lung injury. J Cell Mol Med.
25:1851–1866. 2021.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Misso G, Di Martino MT, De Rosa G, Farooqi
AA, Lombardi A, Campani V, Zarone MR, Gullà A, Tagliaferri P,
Tassone P and Caraglia M: Mir-34: A new weapon against cancer? Mol
Ther Nucleic Acids. 3(e194)2014.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Yin J, Zhao X, Chen X and Shen G: Emodin
suppresses hepatocellular carcinoma growth by regulating macrophage
polarization via microRNA-26a/transforming growth factor beta
1/protein kinase B. Bioengineered. 13:9548–9563. 2022.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Biersack B: Interplay of non-coding RNAs
and approved antimetabolites such as gemcitabine and pemetrexed in
mesothelioma. Noncoding RNA Res. 3:213–225. 2018.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Mousseau MM, Shivakumar KM, Yoo J and
Brown JA: Eight triplex-binding molecules from four chemical
classes broadly recognize the MALAT1 triple helix. Molecules.
30(4277)2025.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Evans LW, Bender A, Burnett L, Godoy L,
Shen Y, Staten D, Zhou T, Angermann JE and Ferguson BS: Emodin and
emodin-rich rhubarb inhibits histone deacetylase (HDAC) activity
and cardiac myocyte hypertrophy. J Nutr Biochem.
79(108339)2020.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Devi PB and Mani S: A promising histone
deactelase inhibitors from secondary metabolites-an in-silico
approach. Research J Pharm Tech. 14:673–684. 2021.
|
|
88
|
Pan FP, Zhou HK, Bu HQ, Chen ZQ, Zhang H,
Xu LP, Tang J, Yu QJ, Chu YQ, Pan J, et al: Emodin enhances the
demethylation by 5-Aza-CdR of pancreatic cancer cell
tumor-suppressor genes P16, RASSF1A and ppENK. Oncol Rep.
35:1941–1949. 2016.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Xu L, Gao J, Huang D, Lin P, Yao D, Yang
F, Zhang Y, Yang X, Wu M and Ye C: Emodin ameliorates
tubulointerstitial fibrosis in obstructed kidneys by inhibiting
EZH2. Biochem Biophys Res Commun. 534:279–285. 2021.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Xiong H, Shi X, Li L, Yang Q, Ye Z, Deng
Y, Li M, Li S, Wu F, Zhang J, et al: Emodin exerts antitumor
effects in cervical cancer cells by reprogramming phospholipid
metabolism through modulation of H3K27ac and H3K27me3. Int J Biol
Macromol. 357(151454)2026.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Wang C, Wu X, Chen M, Duan W, Sun L, Yan M
and Zhang L: Emodin induces apoptosis through caspase 3-dependent
pathway in HK-2 cells. Toxicology. 231:120–128. 2007.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Conway PJ, Dao J, Kovalskyy D, Mahadevan D
and Dray E: Polyploidy in cancer: Causal mechanisms,
cancer-specific consequences, and emerging treatments. Mol Cancer
Ther. 23:638–647. 2024.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Xu L, Liu Y, Chen Y, Zhu R, Li S, Zhang S,
Zhang J, Xie HQ and Zhao B: Emodin inhibits U87 glioblastoma cells
migration by activating aryl hydrocarbon receptor (AhR) signaling
pathway. Ecotoxicol Environ Saf. 234(113357)2022.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Wang Z, Chen H, Chen J, Hong Z, Liao Y,
Zhang Q and Tong H: Emodin sensitizes human pancreatic cancer cells
to EGFR inhibitor through suppressing Stat3 signaling pathway.
Cancer Manag Res. 11:8463–8473. 2019.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Zu C, Qin G, Yang C, Liu N, He A, Zhang M
and Zheng X: Low dose Emodin induces tumor senescence for boosting
breast cancer chemotherapy via silencing NRARP. Biochem Biophys Res
Commun. 505:973–978. 2018.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Chen L, Li J, Cheng Z, Jin F, Shi J, Weng
L, He C, Wang L and Qiu Z: To explore the active components,
targets, and potential effects of emodin in the treatment of
colorectal cancer based on network pharmacology. PPAR Res.
2025(6547135)2025.PubMed/NCBI View Article : Google Scholar
|
|
97
|
McDonald SJ, VanderVeen BN, Velazquez KT,
Enos RT, Fairman CM, Cardaci TD, Fan D and Murphy EA: Therapeutic
potential of emodin for gastrointestinal cancers. Integr Cancer
Ther. 21(15347354211067469)2022.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Song Y, Sheng Z, Xu Y, Dong L, Xu W, Li F,
Wang J, Wu Z, Yang Y, Su Y, et al: Magnetic liposomal emodin
composite with enhanced killing efficiency against breast cancer.
Biomater Sci. 7:867–875. 2019.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Fu M, Tang W, Liu JJ, Gong XQ, Kong L, Yao
XM, Jing M, Cai FY, Li XT and Ju RJ: Combination of targeted
daunorubicin liposomes and targeted emodin liposomes for treatment
of invasive breast cancer. J Drug Target. 28:245–258.
2020.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Sharma N, Garg A, Singh S and Gupta S:
Unravelling the recent trends in pharmacological and
nanotechnological potential of emodin. Lett Appl NanoBioScience.
15:1–25. 2026.
|
|
101
|
Liu J, Xiao S, Huang C, Zhang X, Cai R, Qu
S, Peng Y and Xie L: Emodin nanoparticles-loaded injectable
hydrogel with deep tumor penetration for triple-negative breast
cancer therapy. Biomater Adv. 177(214380)2025.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Zhang T, Dong D, Lu D, Wang S and Wu B:
Cremophor EL-based nanoemulsion enhances transcellular permeation
of emodin through glucuronidation reduction in
UGT1A1-overexpressing MDCKII cells. Int J Pharm. 501:190–198.
2016.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Zhang W, Li L, Wu Y, Li C, Xu Z, Zhang N,
Wang X, Zhao Y, Zu T, He Q, et al: Biomimetic iron-based
nanoparticles remodel immunosuppressive tumor microenvironment for
metabolic immunotherapy. Int J Nanomedicine. 19:9333–9349.
2024.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Ren S, Song L, Tian Y, Zhu L, Guo K, Zhang
H and Wang Z: Emodin-conjugated PEGylation of
Fe3O4 nanoparticles for FI/MRI dual-modal
imaging and therapy in pancreatic cancer. Int J Nanomedicine.
16:7463–7478. 2021.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Sherekar P, Suke SG, Dani R, Upadhyay A
and Ahmad S: Nanoformulation, characterization, and in vivo
pharmacokinetic studies of diosgenin- and emodin-loaded polymeric
nanoparticles. BioNanoSci. 14:164–174. 2024.
|
|
106
|
Liu H, Xu H, Zhang C, Gao M, Gao X, Ma C,
Lv L, Gao D, Deng S, Wang C and Tian Y: Emodin-loaded PLGA-TPGS
nanoparticles combined with heparin sodium-loaded PLGA-TPGS
nanoparticles to enhance chemotherapeutic efficacy against liver
cancer. Pharm Res. 33:2828–2843. 2016.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Zou T, Lan M, Liu F, Li L, Cai T, Tian H
and Cai Y: Emodin-loaded polymer-lipid hybrid nanoparticles enhance
the sensitivity of breast cancer to doxorubicin by inhibiting
epithelial-mesenchymal transition. Cancer Nanotechnol.
12(22)2021.
|
|
108
|
Liu H, Gao M, Xu H, Guan X, Lv L, Deng S,
Zhang C and Tian Y: A promising emodin-loaded poly
(lactic-co-glycolic acid)-d-α-tocopheryl polyethylene glycol 1000
succinate nanoparticles for liver cancer therapy. Pharm Res.
33:217–236. 2016.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Shi Y, Li J, Ren Y, Wang H, Cong Z, Wu G,
Du L, Li H and Zhang X: Pharmacokinetics and tissue distribution of
emodin loaded nanoemulsion in rats. J Drug Deliv Sci Technol.
30:242–249. 2015.
|
|
110
|
Zheng Q, Li S, Li X and Liu R: Advances in
the study of emodin: An update on pharmacological properties and
mechanistic basis. Chin Med. 16(102)2021.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Yang K, Jin MJ, Quan ZS and Piao HR:
Design and synthesis of novel anti-proliferative emodin derivatives
and studies on their cell cycle arrest, apoptosis pathway and
migration. Molecules. 24(884)2019.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Xing M, Ma X, Wang X, Wang H, Xie M, Zhang
Z and Zhou J: Emodin disrupts the Notch1/Nrf2/GPX4 antioxidant
system and promotes renal cell ferroptosis. J Appl Toxicol.
43:1702–1718. 2023.PubMed/NCBI View Article : Google Scholar
|
